Biotech Growth Trust PLC (LON:BIOG) has announced its Fact Sheet as at 31 October 2026 is now available.
Commentary
In October, the NAV per share was -7.4%, the share price was -10.9% and the benchmark NASDAQ Biotechnology Index (net, total return, sterling adjusted) was +1.9%.
During October, broader equity markets experienced a sharp sell-off in technology stocks and a rotation towards more defensive sectors, including healthcare. Despite generally resilient corporate earnings, investor scrutiny intensified around the significant capital being deployed towards artificial intelligence infrastructure and whether these investments will generate adequate returns.
Within biotechnology, the defensive rotation resulted in strength in the large cap names, with smaller biotechnology companies continuing to face significant selling pressure. Volatility in the 10-year Treasury yield remained high as well, exacerbating this divergence given that small cap stocks are more sensitive to interest rate volatility. The Company’s overweighting in small caps and underweighting in large caps resulted in significant underperformance versus the benchmark.
Another factor impacting the Company’s performance was a significant reduction in the gross exposure of biotech positions by hedge funds. Morgan Stanley reported that the most crowded biotech longs were being sold and the most crowded biotech shorts were being bought during the month. This degrossing meant that many of the companies we consider high quality that hedge funds held long suffered the largest share price declines, while many of the lower quality companies that had been popular shorts outperformed as funds covered their short positions. Given that the Company held many of these popular longs, this degrossing effect artificially depressed the share prices of many of those names. In light of these developments, the Company took a more defensive posture, reducing small and mid cap names in the portfolio and increasing our exposure to large caps. We continue to believe that as 10-year Treasury yields stabilise, shares of small and mid-cap biotech companies will eventually recover from these transiently depressed levels.
Following the month end, the U.S. midterm elections delivered a sweeping Democratic victory, with Democrats taking decisive control of both chambers of Congress. It is unclear what Democrats will be able to achieve legislatively given that President Trump is likely to veto many of their proposed bills. However, it is possible that there will be some headline noise for the biopharmaceutical industry in 2027 if Democrats propose new policies to lower drug prices in the U.S. We do not expect any meaningful changes to drug pricing in the medium term but will continue to monitor the political situation.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.







































